The antiphospholipid antibody syndrome: Diagnosis, skin manifestations and current therapy

Clinical and Experimental Rheumatology

Volumn 24, Issue SUPPL. 40, 2006, Pages

  Asherson, R A ^a,f   Frances C ^b   Iaccarino, L ^c   Khamashta, M A ^d   Malacarne, F ^e   Piette, J C ^b   Tincani, A ^e   Doria, Andrea ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF PADOVA   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF BRESCIA   (Italy)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

Anticoagulation; Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Classification criteria; Fetal Loss; Livedo reticularis; Low dose aspirin; Pregnancy; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CAPTOPRIL; CORTICOSTEROID; DANAZOL; DIPYRIDAMOLE; ENCEPHALITIS VACCINE; ESTROGEN; FRESH FROZEN PLASMA; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; RITUXIMAB; STEROID; THIAZIDE DIURETIC AGENT; WARFARIN; YELLOW FEVER VACCINE;

ANETODERMA; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLEEDING; BLOOD VESSEL OCCLUSION; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG INDICATION; GANGRENE; HUMAN; INFECTION; LABORATORY TEST; LIVEDO RETICULARIS; LONG TERM CARE; MICROANGIOPATHY; MORBIDITY; MULTIPLE ORGAN FAILURE; NAIL DISEASE; NONHUMAN; PATIENT MONITORING; PLASMAPHERESIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; SKIN NECROSIS; SKIN ULCER; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; VASCULITIS; VEIN THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; SKIN DISEASES; SKIN DISEASES, VASCULAR; THROMBOSIS;

EID: 33645026788     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. WILSON WA, GHARAVI AE, KOIKE T et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
2. BRANDT JT, TRIPLETT DA, ALVING B, SCHARRER I: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
3. TINCANI A, ALLEGRI F, SANMARCO M et al.: Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-83.
4. REBER G, TINCANI A, SANMARCO M, de MOERLOOSE P, BOFFA MC: Variability of anti-β2 glycoprotein I antibodies measurement by commercial assays. Thromb Haemost 2005; 94: 655-72.
5. TINCANI A, ALLEGRI F, BALESTRIERI G et al.: Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid anti-bodies. Thromb Res 2004; 114: 553-8.
6. NEVILLE C, RAUCH J, KASSIS J et al.: Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003; 90: 108-15.
7. FRANCES C, NIANG S, LAFFITTE E et al.: Dermatologic manifestations of antiphospholipid syndrome. Two hundred consecutive cases. Arthritis Rheum 2005; 52: 1785-93.
8. ASHERSON RA, CERVERA R, PIETTE JC et al.: Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80: 355-77.
9. CERVERA R, PIETTE JC, FONT J et al.: Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
10. SPARSA A, PIETTE JC, WECHSLER B, AMOURA Z, FRANCÈS C: Anetoderma and its prothrombotic abnormalities. J Am Acad Dermatol 2003; 49: 1008-12.
11. ASHERSON RA: The catastrophic antiphospholipid syndrome J Rheumatol 1992: 19: 508-12.
12. PIETTE JC, CERVERA R, LEVY RA, NASONOV EL, TRIPLETT DA, SHOENFELD Y: The catastrophic antiphospholipid syndrome - Asherson's syndrome. Ann Med Interne 2003; 154: 195-6
13. ASHERSON RA, CERVERA R, PIETTE JC et al.: Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195-207.
14. ASHERSON RA, SHOENFELD Y: The role of infection in the pathogenesis of the catastrophic antiphospholipid syndrome. Molecular mimicry. J Rheumatology 2000; 27: 12-5.
15. MERRILL J, ASHERSON RA: Catastrophic antiphospholipid syndrome. Nature 2005, in press.
16. KOENIG M, ROY M, BACCOT S, CUILLERON M, DE FILIPPIS JP, CATHEBRAS P: Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol 2005 24: 166-8.
17. ESPINOSA G, BUCCIARELLI S, CERVERA R et al.: Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004; 63: 730-6.
18. PIERANGELI SS, GIRARDI G, VEGA-OSTERTAG M, LIU X, ESPINOLA RG, SALMON J: Requirement of activation of complement C3 and C5 for antiphospbolipid antibody mediated thrombosis. Arthritis Rheum 2005; 52: 2120-4.
19. SALMON JE, GIRARDI G, HOLERS VM: Activation of complement mediates antiphospholipid antibody -induced pregnancy loss. Lupus 2003; 12: 535-8.
20. HART ML, KEONZO KA, SHAFFER LA et al.: Gastrointestinal Ischemia - reperfusion is lectin complement pathway dependent without involving C1q. J Immunol 2005; 174: 6373-80.
21. FLEMING SD, EGAN RE, CHAI C et al.: Anti-phospholipid antibodies restore mesenteric ischemia reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol 2005; 173: 7055-61.
22. KHAMASHTA MA: Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun 2000; 15: 249-53.
23. PETRI M: Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort Perspective. Scand J Rheumatol 1996; 25: 191-3.
24. KHAMASHTA MA: Management of thrombosis in the antiphospholipid syndrome. In: KHAMASHTA MA (Ed.): Hughes Syndrome: Antiphospholipid Syndrome. London: Springer-Verlag, 2000: 391-6.
25. KHAMASHTA MA, CUADRADO MJ, MUJIC F et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
26. ROSOVE MH, BREWER PM: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117:303-8.
27. CROWTHER MA, GINSBERG JS, JULIAN J et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid anti-body syndrome. N Engl J Med 2003; 349: 1133-8.
28. FINAZZI G, MARCHIOLI R, BRANCACCIO V et al.: A randomized clinical trial of high-intensity warfarin vs. conventional anti-thrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
29. RUIZ-IRASTORZA G, KHAMASHTA MA, HUNT BJ et al.: Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 1164-9.
30. KHAMASHTA MA, HUNT BJ: Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome ? No. J Thromb Haemost 2005; 3: 844-5.
31. DERKSEN RH, KHAMASHTA MA, BRANCH DW: Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50: 1028-39.
32. STONE S, HUNT BJ, KHAMASHTA MA, BEWLEY SJ, NELSON-PIERCY C: Primary antiphospholipid syndrome in pregnancy: an analysis of outcome in a cohort of 33 women treated with a rigorous protocol. J Thromb Haemost 2005; 3: 243-5.
33. TOUBI E, KRAUSE I, FRASER A et al.: Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005; 23: 499-504
34. ASHERSON RA, CERVERA R, de GROOT PG et al.: Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-4.